Literature DB >> 7956613

Wedged hepatic venous pressure reflects portal venous pressure during vasoactive drug administration in nonalcoholic cirrhosis.

T Iwao1, A Toyonaga, M Ikegami, M Sumino, K Oho, M Sakaki, H Shigemori, M Nakayama, K Tanikawa.   

Abstract

Hepatic venous catheterization is widely used to assess portal pressure. However, it remains unclear whether wedged hepatic venous pressure is a close indicator of portal venous pressure during vasoactive drug administration in nonalcoholic cirrhosis. To address this issue, we analyzed the data from our previous published studies. Forty patients with nonalcoholic cirrhosis (HBV infection in five, HCV infection in 28, and cryptogenic in seven) were available in this analysis. A vasoconstrictor (N = 14), vasodilator (N = 10), or combination (N = 16) was administered. The agreement of the changes between portal and wedged hepatic venous pressures during pharmacological manipulation was assessed by an intraclass correlation coefficient. The intraclass correlation coefficient in each subgroup was more than 0.60 (0.62 in vasoconstrictor group, 0.87 in vasodilator group, and 0.73 in combination group). When the analysis was performed according to the cause of liver disease, the values were 0.67 in HBV infection, 0.73 in HCV infection, and 0.74 in cryptogenic cirrhosis. These results suggest that wedged hepatic venous pressure reflects portal venous pressure during vasoactive drug administration in patients with nonalcoholic cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7956613     DOI: 10.1007/BF02087663

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

2.  Percutaneous transhepatic catheterization of the portal vein for the study of portal hemodynamics and shunts. A preliminary report.

Authors:  K Okuda; K Suzuki; H Musha; N Arimuzu
Journal:  Gastroenterology       Date:  1977-08       Impact factor: 22.682

3.  Development of large spleno-adreno-renal shunt after endoscopic sclerotherapy.

Authors:  J B Dilawari; G S Raju; Y K Chawla
Journal:  Gastroenterology       Date:  1989-08       Impact factor: 22.682

Review 4.  Drug therapy of portal hypertension.

Authors:  R J Groszmann
Journal:  Am J Gastroenterol       Date:  1987-02       Impact factor: 10.864

5.  Effect of pharmacological agents on portal hypertension: a haemodynamic appraisal.

Authors:  J Bosch
Journal:  Clin Gastroenterol       Date:  1985-01

6.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

7.  Developing criteria for establishing interrater reliability of specific items: applications to assessment of adaptive behavior.

Authors:  D V Cicchetti; S A Sparrow
Journal:  Am J Ment Defic       Date:  1981-09

8.  Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis.

Authors:  J Bosch; R Masti; D Kravetz; J Bruix; J Gaya; J Rigau; J Rodes
Journal:  Hepatology       Date:  1984 Nov-Dec       Impact factor: 17.425

9.  Hemodynamic study during transdermal application of nitroglycerin tape in patients with cirrhosis.

Authors:  T Iwao; A Toyonaga; M Sumino; K Takagi; K Ohkubo; R Inoue; K Tanikawa
Journal:  Hepatology       Date:  1991-01       Impact factor: 17.425

10.  Presinusoidal portal hypertension in non-alcoholic cirrhosis.

Authors:  G Pomier-Layrargues; D Kusielewicz; B Willems; J P Villeneuve; D Marleau; J Côté; P M Huet
Journal:  Hepatology       Date:  1985 May-Jun       Impact factor: 17.425

View more
  5 in total

1.  Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding.

Authors:  D Patch; A Armonis; C Sabin; K Christopoulou; L Greenslade; A McCormick; R Dick; A K Burroughs
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

2.  Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis.

Authors:  S Sugano; T Kawafune; T Okajima; K Ishii; M Watanabe; N Takamura
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

3.  Chronic splanchnic hemodynamic effects of low-dose transdermal nitroglycerin versus low-dose transdermal nitroglycerin plus spironolactone in patients with cirrhosis.

Authors:  S Sugano; T Suzuki; M Nishio; H Makino; T Okajima
Journal:  Dig Dis Sci       Date:  1997-03       Impact factor: 3.199

Review 4.  Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence.

Authors:  U Thalheimer; M Mela; D Patch; A K Burroughs
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

5.  Portohepatic gradient and portal hemodynamics in patients with cirrhosis due to hepatitis C virus infection.

Authors:  A Deplano; V Migaleddu; A Pischedda; G Garrucciu; G Gregu; C Multinu; M Piredda; A Tocco; F Urigo; P A Cossu; A Solinas
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.